These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 23962310

  • 1. Discovery techniques for calcitonin gene-related peptide receptor antagonists for potential antimigraine therapies.
    Labruijere S, Ibrahimi K, Chan KY, Maassenvandenbrink A.
    Expert Opin Drug Discov; 2013 Nov; 8(11):1309-23. PubMed ID: 23962310
    [Abstract] [Full Text] [Related]

  • 2. CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment.
    Edvinsson L.
    Br J Clin Pharmacol; 2015 Aug; 80(2):193-9. PubMed ID: 25731075
    [Abstract] [Full Text] [Related]

  • 3. Calcitonin gene-related peptide receptor antagonists: new therapeutic agents for migraine.
    Bell IM.
    J Med Chem; 2014 Oct 09; 57(19):7838-58. PubMed ID: 24960305
    [Abstract] [Full Text] [Related]

  • 4. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM.
    Expert Opin Drug Metab Toxicol; 2018 Jan 09; 14(1):25-41. PubMed ID: 29226741
    [Abstract] [Full Text] [Related]

  • 5. The relevance of preclinical research models for the development of antimigraine drugs: focus on 5-HT(1B/1D) and CGRP receptors.
    Gupta S, Villalón CM.
    Pharmacol Ther; 2010 Oct 09; 128(1):170-90. PubMed ID: 20655327
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME, Walter S, Rapoport AM.
    Headache; 2013 Sep 09; 53(8):1230-44. PubMed ID: 23848260
    [Abstract] [Full Text] [Related]

  • 9. Potential mechanisms of prospective antimigraine drugs: a focus on vascular (side) effects.
    Chan KY, Vermeersch S, de Hoon J, Villalón CM, Maassenvandenbrink A.
    Pharmacol Ther; 2011 Mar 09; 129(3):332-51. PubMed ID: 21130807
    [Abstract] [Full Text] [Related]

  • 10. Activation of 5-hydroxytryptamine1B/1D/1F receptors as a mechanism of action of antimigraine drugs.
    Ramírez Rosas MB, Labruijere S, Villalón CM, Maassen Vandenbrink A.
    Expert Opin Pharmacother; 2013 Aug 09; 14(12):1599-610. PubMed ID: 23815106
    [Abstract] [Full Text] [Related]

  • 11. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM, Olesen J.
    Pharmacol Ther; 2009 Dec 09; 124(3):309-23. PubMed ID: 19796656
    [Abstract] [Full Text] [Related]

  • 12. Review of dose-response curves for acute antimigraine drugs: triptans, 5-HT1F agonists and CGRP antagonists.
    Hougaard A, Tfelt-Hansen P.
    Expert Opin Drug Metab Toxicol; 2015 Dec 09; 11(9):1409-18. PubMed ID: 26095133
    [Abstract] [Full Text] [Related]

  • 13. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
    Tajti J, Csáti A, Vécsei L.
    Expert Opin Drug Metab Toxicol; 2014 Nov 09; 10(11):1509-20. PubMed ID: 25253587
    [Abstract] [Full Text] [Related]

  • 14. CGRP receptor antagonists: toward a novel migraine therapy.
    Salvatore CA, Kane SA.
    Curr Pharm Biotechnol; 2011 Oct 09; 12(10):1671-80. PubMed ID: 21466447
    [Abstract] [Full Text] [Related]

  • 15. In vivo quantification of calcitonin gene-related peptide receptor occupancy by telcagepant in rhesus monkey and human brain using the positron emission tomography tracer [11C]MK-4232.
    Hostetler ED, Joshi AD, Sanabria-Bohórquez S, Fan H, Zeng Z, Purcell M, Gantert L, Riffel K, Williams M, O'Malley S, Miller P, Selnick HG, Gallicchio SN, Bell IM, Salvatore CA, Kane SA, Li CC, Hargreaves RJ, de Groot T, Bormans G, Van Hecken A, Derdelinckx I, de Hoon J, Reynders T, Declercq R, De Lepeleire I, Kennedy WP, Blanchard R, Marcantonio EE, Sur C, Cook JJ, Van Laere K, Evelhoch JL.
    J Pharmacol Exp Ther; 2013 Nov 09; 347(2):478-86. PubMed ID: 23975906
    [Abstract] [Full Text] [Related]

  • 16. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
    Salvatore CA, Hershey JC, Corcoran HA, Fay JF, Johnston VK, Moore EL, Mosser SD, Burgey CS, Paone DV, Shaw AW, Graham SL, Vacca JP, Williams TM, Koblan KS, Kane SA.
    J Pharmacol Exp Ther; 2008 Feb 09; 324(2):416-21. PubMed ID: 18039958
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Targeting CGRP: A New Era for Migraine Treatment.
    Wrobel Goldberg S, Silberstein SD.
    CNS Drugs; 2015 Jun 09; 29(6):443-52. PubMed ID: 26138383
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.